Introduction
Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple clinical conditions. PH is defined by a mean pulmonary artery pressure (mPAP) ≥25 mmHg at rest. Right heart catheterization (RHC) is required to confirm the diagnosis of PH, and transthoracic echocardiography is the most important non-invasive method for screening and assessment of PH [1] . However, the most widely used echocardiographic parameter, tricuspid regurgitant jet (TR) velocity, does not accurately reflect invasive pressures and is not present in all patients [2] .
Exercise testing is a well-established and widely used tool for clinical assessment of patients with cardiopulmonary disease [3] [4] [5] . Cardiopulmonary exercise testing (CPET) is useful for the evaluation of elevated pulmonary pressure, either as a primary pathophysiological process or a consequence of other cardiopulmonary conditions [1] . Oxygen uptake (V O 2 ) at peak and aerobic capacity is a standard metric used to define the limits of the cardiopulmonary system, and is inversely associated with pulmonary artery pressure at rest and during exercise [6] [7] [8] . Moreover, CPET variables, including the relationship between minute ventilation and carbon dioxide production (V E/V CO 2 slope) and end-tidal carbon dioxide pressure (PETCO 2 ) at the anaerobic threshold (AT), can be used to detect the likelihood of pulmonary artery hypertension (PAH) and secondary PH. However, given there is no generally accepted Abstract Cardiopulmonary exercise testing (CPET) is useful for the evaluation of patients with suspected or confirmed pulmonary hypertension (PH). End-tidal carbon dioxide pressure (PETCO 2 ) during exercise is reduced with elevated pulmonary artery pressure. However, the utility of ventilatory parameters such as CPET for detecting PH remains unclear. We conducted a review in 155 patients who underwent right heart catheterization and CPET. Fifty-nine patients had PH [mean pulmonary arterial pressure (mPAP) ≥25 mmHg]. There was an inverse correlation between PETCO 2 at the anaerobic threshold (AT) and mPAP (r = −0.66; P < 0.01). Multiple regression analysis showed that PETCO 2 at the AT was independently associated with an elevated mPAP (P = 0.04). The sensitivity and specificity of CPET for PH were 80 and 86%, respectively, when the cut-off value identified by receiver operating characteristic curve analysis for PETCO 2 at the AT was ≤34.7 mmHg. A combination of echocardiography and CPET improved the sensitivity in detecting PH without markedly reducing specificity (sensitivity 87%, specificity 85%). Evaluation of PETCO 2 at the AT is useful for estimating pulmonary pressure. A combination of CPET and standardization of CPET in PH [9, 10] , and no single CPET variable can independently be used to diagnose PH, CPET is currently not prevalent in clinical practice. Thus, the aim of the present study was to determine the utility of the ventilatory parameters of CPET as markers for cardiopulmonary hemodynamics obtained by RHC, and for detection of PH.
Materials and methods

Patients
We investigated pulmonary circulation and exercise pathophysiology in patients who underwent RHC and CPET between 2012 and 2016 at Hiroshima University Hospital. The exclusion criteria were as follows: (1) hemodynamic instability; (2) serious respiratory disease; (3) pulmonary capillary wedge pressure (PCWP) >15 mmHg; (4) patients undergoing CPET over 1 month before or after RHC; and (5) patients unable to reach the AT in a CPET test. Regarding patient inclusion, PAH was defined as an mPAP ≥25 mmHg and PCWP ≤15 mmHg. Chronic thromboembolic pulmonary hypertension (CTEPH) was defined as an mPAP ≥25 mmHg, PCWP ≤15 mmHg, and a ventilation/ perfusion (V/Q) nuclear medicine scan consistent with thromboembolic disease. All patients underwent a detailed clinical workup, including medical history, physical examination, electrocardiogram, laboratory testing (N-terminal pro-brain natriuretic peptide (NT-proBNP), uric acid, and hemoglobin), and pulmonary function testing (vital capacity, forced expiratory volume in 1 s, and diffusing capacity of the lung for carbon monoxide per unit alveolar volume). Informed consent was obtained from each patient, and the ethics committee at Hiroshima University approved this study.
Cardiopulmonary exercise testing
Symptom-limited CPET was performed on a cycle ergometer using a ramp protocol. The protocol consisted of 3 min of rest, 3 min of unloaded cycling at 50 revolutions per min, followed by a progressively increasing work rate of 5-10 W/min to maximum tolerance. Gas exchange variables were measured breath-by-breath, and presented as nine-breath moving average using a diagnostic system (AE310s Respiromonitor; Minato Medical Science; Osaka, Japan). Twelve-lead electrocardiogram and pulse oximetry were monitored continuously. Blood pressure was measured using an automatic cuff manometer every minute. The AT was determined manually using a combination of the V-slope method and ventilator equivalents for oxygen. The V E/V CO 2 slope was obtained by linear regression analysis of the relationship between V E and V CO 2 during exercise prior to the respiratory compensation.
Echocardiography
Transthoracic echocardiography was performed prior to RHC in accordance with standard guidelines. Two-dimensional and color flow-guided continuous wave Doppler echocardiographic recordings were obtained by experienced cardiac sonographers. The left ventricular ejection fraction and TR velocity were measured.
Right heart catheterization
Hemodynamic measurements were performed with patients in the supine position, and included PCWP, mPAP, and right atrial pressure. Cardiac output (CO) was determined by thermodilution with cold, refrigerated 5% glucose. Pulmonary vascular resistance (PVR) was calculated using the standard formula, PVR = [mPAP − PCWP]/CO.
Statistical analysis
Data are presented as median with inter-quartile range for non-normally distributed variables, and as mean ± standard deviation for normally distributed continuous variables. Categorical variables are presented as numbers and percentages. The characteristics of three groups of patients (no PH, borderline PH, and PH) were compared by analysis of variance (and Tukey's post hoc test) or Kruskal-Wallis analysis for parametric and nonparametric data, respectively. Differences in categorical data were tested by Chisquared analysis. The correlation between the AT, PETCO 2 at the AT, V E/V CO 2 slope, and hemodynamic parameters were compared by Pearson correlations. Multiple linear regression analysis was used to determine the independent predictors of mPAP. Univariate predictors of mPAP with P < 0.05 were entered into the multivariate model. Independent predictors and their regression coefficients were calculated. Receiver operating characteristic (ROC) analysis was used to assess the detectability, and to generate the optimal cut-off values of the ventilatory parameters for predicting pulmonary hypertension (mPAP ≥25 mmHg). P < 0.05 was considered statistically significant. All analyses were conducted using statistical software (JMP 12.2.0; SAS Institute Inc., Cary, NC, USA).
Results
One hundred fifty-five patients were included in this cross-sectional study. The demographic characteristics of Data are presented as mean ± standard deviation, median (IQR), or n (%) ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker, AT anaerobic threshold, BMI body mass index, CO cardiac output, CTEPH chronic thromboembolic pulmonary hypertension, DLCO/VA diffuse capacity of lung for carbon monoxide per unit alveolar volume, FEV 1 forced expiratory volume in 1 s, LHD left heart disease, LVEF left ventricular ejection fraction, NT-pro BNP N-terminal pro-brain natriuretic peptide, NYHA New York Heart Association, mPAP mean pulmonary arterial pressure, PAH pulmonary artery hypertension, PDE phosphodiesterase, PETCO 2 end-tidal carbon dioxide pressure, PH pulmonary hypertension, PVR pulmonary vascular resistance, PCWP pulmonary capillary wedge pressure, VC vital capacity, TR tricuspid regurgitation jet, UA uric acid, V E/V CO 2 slope relationship between minute ventilation and carbon dioxide production, V O 2 /W oxygen uptake # P < 0.05, vs. no PH group $ P < 0.05, vs. borderline PH group patients are shown in Table 1 . We diagnosed 41 patients with PAH (22 patients with idiopathic PAH, 13 patients with connective tissue disease, and 6 patients with congenital heart disease), 34 with CTEPH, and 67 with left heart disease (LHD). Thirteen patients were not diagnosed with PAH, CTEPH, or LHD, although PH was suspected by echocardiography. These patients were therefore categorized as others. In 16 patients diagnosed with PAH or CTEPH, mPAP <25 mmHg was achieved in response to treatment. Among 21 patients, two of whom had an mPAP ≥25 mmHg, TR was not detected. The relationships between CPET variables and hemodynamic parameters are shown in Fig. 1 . CPET variables were significantly correlated with mPAP and PVR. Notably, PETCO 2 at the AT showed a strong correlation with mPAP and PVR. PETCO 2 at the AT was used as a variable for simple and multiple regression analysis for mPAP ≥25 mmHg because PH was associated with significantly decreased PETCO 2 at the AT compared with no PH and borderline PH (P < 0.01 and P < 0.01, respectively, by Tukey's post hoc test). Multiple regression analysis adjusted for the presence of New York Heart Association III or IV diagnosis, NT-proBNP, hemoglobin, left ventricular ejection fraction, TR velocity, AT, and V E/V CO 2 slope showed that PETCO 2 at the AT was independently associated with elevated mPAP ( Table 2 ).
The ROC curves of CPET variables for predicting mPAP ≥25 mmHg are shown in Fig. 2 . The cut-off values for prediction of mPAP ≥25 mmHg were 10.0 ml/kg/min for the AT [area under the curve (AUC) = 0.753], 34.7 mmHg for PETCO 2 at the AT (AUC = 0.873), and 37.5 for V E/V CO 2 slope (AUC = 0.818). A comparison of echocardiography, CPET, and a combination of the two for detecting PH is shown in Table 3 . Echocardiography revealed a sensitivity for diagnosis of mPAP ≥25 mmHg of 72%, and a specificity of 95% when the cut-off TR velocity value was 3.4 m/s, which suggested a high probability of PH when the European Society of Cardiology/European Respiratory Society guideline [1] was used. CPET had a sensitivity of detecting mPAP ≥25 mmHg of 80%, and a specificity of 86% when the cut-off PETCO 2 at the AT of 34.7 mmHg was used. The combination of echocardiography and CPET increased the sensitivity of diagnosing PH without markedly decreasing the specificity (sensitivity 87%, specificity 85%).
Discussion
In the present study, we provide novel evidence that evaluation of PETCO 2 at the AT obtained by CPET is useful for the evaluation of elevated pulmonary pressure. CPET is increasingly used for the evaluation of exercise capacity Fig. 1 Relationships between cardiopulmonary exercise testing (CPET) variables and hemodynamic parameters. a Mean pulmonary arterial pressure (mPAP) and anaerobic threshold (AT). b mPAP and end-tidal carbon dioxide pressure (PETCO 2 ) at the AT. c mPAP and the relationship between minute ventilation and carbon dioxide production (V E/V CO 2 slope). d Pulmonary vascular resistance (PVR) and the AT. e PVR and PETCO 2 at the AT. f PVR and V E/V CO 2 slope. g Cardiac output (CO) and the AT. h CO and PETCO 2 at the AT. i CO and V E/V CO 2 slope and prognosis in patients with heart or lung disease [11, 12] . The mismatching of ventilation to perfusion is a common physiological abnormality that accounts for much of the increased ventilator response to exercise in a number of diseases, including PAH and diseases that lead to secondary PH such as LHD, pulmonary disease, and chronic thromboembolic disease [13] . The gas exchange response in CPET of patients with PAH and those with secondary PH appear strikingly similar, although the pathophysiological mechanisms that lead to these exercise-related abnormalities are different [10] . In the present study, we demonstrated the utility of ventilatory parameters during exercise for evaluating the pulmonary circulation as a non-invasive diagnostic approach. PETCO 2 , which is normally determined by CO 2 production, alveolar ventilation, pulmonary perfusion, and the degree of V/Q matching in the lung, and which increases by 5-10 mmHg above resting values at the AT, is considered a strong prognostic marker in various cardiopulmonary conditions [10, 13, 14] . A previous study reported that PETCO 2 during exercise decreased in proportion to the decrease in age-predicted peak V O 2 , while PETCO 2 values at rest and at the AT were reduced as mPAP increased in PAH [15] . Other studies also reported a significant correlation of PETCO 2 during exercise with PVR, and a close relationship between PETCO 2 during exercise and mPAP in PAH [16, 17] . In CTEPH, ventilatory efficiency is impaired because of increased physiologic ventilatory dead space fraction as a result of V/Q matching. There are several reports of significant differences in gas exchange between CTEPH and PAH [18, 19] . In LHD, the presence of PH is independently associated with poor prognosis [20] [21] [22] . Additionally, reduced PETCO 2 during exercise, which is dependent on V/Q matching caused by a reduced rate of increasing pulmonary blood flow, reflects elevated mPAP and impairments in the functional, ventilatory, and cardiac performance response to exercise [23] [24] [25] . The meaning of mPAP ≥25 mmHg is different in pre-and postcapillary PH. In our study, patients with a PCWP >15 mmHg were excluded. It might be necessary to separately assess the optimal cut-off values of the ventilatory parameters for predicting PH (mPAP ≥25 mmHg) according to etiology.
Our data showed a significant correlation of PETCO 2 at the AT with mPAP regardless of pathophysiology, while the reduction in PETCO 2 at the AT was different between PAH, CTEPH, and LHD. Moreover, the reduced PETCO 2 at the AT had a high sensitivity and specificity in diagnosing PH. In PAH and CTEPH, elevated PVR caused by vasculopathy and pulmonary artery occlusion is associated with elevated mPAP at rest and an insufficient increase of pulmonary blood flow during exercise, which leads to a V/Q mismatch. Similarly, in LHD, elevated PCWP is associated with elevated mPAP at rest and an insufficient increase of pulmonary blood flow during exercise, leading to a V/Q mismatch.
Although echocardiography is currently used to detect elevated pulmonary pressure, it is associated with both overestimation and underestimation, and does not always identify PH [2, 26, 27] . When the screening algorithm of the DETECT study was used, including echocardiography and the diffusing capacity of the lung for carbon monoxide, the rate of missed diagnosis was reduced in systemic sclerosis (SSc) patients with PAH [28] . Moreover, Na et al. recently reported that stress echocardiography improved the sensitivity for detecting PH to 95.2% compared with 72.2% in echocardiography at rest in patients with SSc [29] .
Assessing hemodynamics during exercise is considered useful for identifying abnormal pulmonary circulation, and may help to identify patients with PH at an early stage [30] . CPET provides information on pulmonary hemodynamics, although it is not widely used for screening for PH. Markowitz et al. reported a sensitivity, specificity, and accuracy of V E/V CO 2 at the AT obtained by CPET for the pulmonary vascular limit (PVR ≥120 dyne s/cm 5 ) of 79, 88, and 85%, respectively [31] . Our data indicate that PETCO 2 at the AT obtained by CPET can be used to evaluate pulmonary pressure in patients without TR, and that a combination of echocardiography and CPET can increase the sensitivity of diagnosing PH, without markedly decreasing specificity. Compared with echocardiography, operator skill is a less important factor in CPET, and the interobserver error is low. Overall, these data suggest that the accuracy of previous screening algorithms for PH may be increased by the inclusion of CPET parameters.
Limitations
This was a retrospective cross-sectional, single-center study that targeted heterogeneous populations with different etiologies. Therefore, we could not add a control group of normal mPAP. Although we excluded patients with PCWP >15 mmHg, many patients in the no PH group had LHD. The clinical significance of PETCO 2 may partially depend on the etiology of the disease. However, the number of subjects in the present study was not sufficient to assess disease-specific characteristics. Although we have examined the patients with reduced mPAP after PH therapy, we could not compare PETCO 2 before and after PH therapy. Exercise-induced right-to-left shunting was shown to have a potential impact on the relationship between gas exchange patterns and hemodynamic status [32] . Nevertheless, we found that evaluating PETCO 2 at the AT was a useful marker for screening in PH. Prospective studies in a more general population are necessary to evaluate the utility of PETCO 2 at the AT in a diagnostic algorithm.
Conclusions
The results of this study showed that evaluation of PETCO 2 obtained by CPET is useful for detecting and assessing PH.
